- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00474812
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. Determine the overall survival, including median survival, of patients with metastatic adenocarcinoma of the pancreas treated with dasatinib.
SECONDARY OBJECTIVES:
I. Determine the effects of this drug on quantities of circulating tumor cells in these patients.
II. Determine the time to progression in patients treated with this drug. III. Determine pre- and post-drug fat-free mass and gait speed in patients treated with this drug.
IV. Evaluate the toxicity of this drug in these patients. V. Evaluate objective response rate in patients treated with this drug.
OUTLINE: This is an open-label, multicenter study.
Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection at baseline and during days 25-31. Samples are analyzed for quantification of circulating tumor cells. Patients also undergo analysis of fat-free mass and gait speed at baseline and at 1, 2, and 6 months.
After completion of study treatment, patients are followed periodically.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of the pancreas
- Metastatic disease
- Measurable or evaluable/nonmeasurable disease
- No known brain metastases
- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
- Life expectancy > 12 weeks
- Absolute granulocyte count >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Hemoglobin > 8.5 g/dL
- Bilirubin =< 1.5 times upper limit of normal (ULN)
- AST and ALT =< 2.5 times ULN
- Creatinine =< 2.0 mg/dL
- Not pregnant or nursing
- No history of allergic reactions attributed to compounds of similar chemical or biological composition to dasatinib
- No QTc prolongation (i.e., QTc interval >= 480 msecs [Fridericia correction]) or other significant ECG abnormalities
- LVEF normal by MUGA scan
No condition that impairs ability to swallow and retain dasatinib tablets, including any of the following:
- Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
- Prior surgical procedures affecting absorption
- Active peptic ulcer disease
No clinically significant cardiovascular disease, including any of the following:
- Myocardial infarction or ventricular tachyarrhythmia within the past 6 months
- Major conduction abnormality (unless a cardiac pacemaker is present)
- Recovered from all prior therapy
- More than 4 weeks since prior adjuvant chemotherapy (6 weeks for nitrosoureas or mitomycin C) and/or radiotherapy
- No prior chemotherapy for metastatic disease
- More than 4 weeks since prior EGFR inhibitors (e.g., imatinib mesylate, gefitinib, erlotinib hydrochloride, or lapatinib ditosylate)
- No prior EGFR inhibitors that target Src kinases
- At least 7 days since prior and no concurrent agents with proarrhythmic potential
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent grapefruit or grapefruit juice
- No other concurrent anticancer agents or therapies
- No concurrent systemic antacids (i.e., H2-receptor antagonists and proton pump inhibitors) [Locally acting antacids (e.g., Maalox, Mylanta) allowed within either 2 hours before or 2 hours after dasatinib therapy]
No concurrent uncontrolled illness, including, but not limited to, any of the following:
- Ongoing or active infection
- History of significant bleeding disorder, including congenital (von Willebrand's disease) or acquired (anti-factor VIII antibodies) disorders
- Large pleural effusions
- Psychiatric illness or social situation that would preclude study compliance
- More than 7 days since prior and no concurrent CYP3A4 inducers or inhibitors
- No other concurrent investigational agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dasatinib Treatment
Patients receive oral dasatinib twice daily on days 1-28.
|
Other Names:
Correlative study
Correlative study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Overall Survival
Time Frame: assessed up to 24 months
|
From the date of onset of treatment to the date of death and to the date of last follow-up for those still alive, assessed up to 24 months
|
assessed up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (Complete Response, Partial Response, or Stable Disease), Evaluated Using the New International Criteria Proposed by the RECIST Committee
Time Frame: Up to 5 years
|
Response is defined as CR (Complete Response), PR (Partial Response) or SD (Stable Disease) per Response Evaluation Criteria in Solid Tumor (RECIST criteria).
Possible evaluations include: CR: Disappearance of all target lesions.
PR: At least a 30% decrease in the size of target lesions.
SD: neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as progressive disease (PD).
Progressive disease (PD) is defined as: at least a 20% increase in the sum of the LD of target lesions.
|
Up to 5 years
|
Median Progression Free Survival (PFS)
Time Frame: Up to 5 years
|
Number of months patients were free of disease progression, defined as < 20% increase in the sum of the LD of target lesions nor the appearance of one or more new lesions.
|
Up to 5 years
|
Gait Speed
Time Frame: baseline
|
Gait speed, determined by a 4 meter walk along a properly measured stretch of hallway while being timed with a stopwatch.
|
baseline
|
Gait Speed
Time Frame: at 8 weeks
|
Gait speed, determined by a 4 meter walk along a properly measured stretch of hallway while being timed with a stopwatch.
|
at 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charles Nock, Case Western Reserve University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Adenocarcinoma
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Dasatinib
Other Study ID Numbers
- NCI-2009-00228 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U01CA062502 (U.S. NIH Grant/Contract)
- CDR0000546554
- CASE 5206 (Other Identifier: Case Western Reserve University)
- 7828 (Other Identifier: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma of the Pancreas
-
Centre Leon BerardMerck Sharp & Dohme LLC; Debiopharm International SACompletedAdenocarcinoma of the Pancreas | Adenocarcinoma of the Rectum | Adenocarcinoma of the ColonFrance
-
Samyang Biopharmaceuticals CorporationUnknownMetastatic Adenocarcinoma of the Pancreas | Recurrent Adenocarcinoma of the PancreasKorea, Republic of
-
Kyowa Hakko Kirin Pharma, Inc.Teva PharmaCompletedAdenocarcinoma of the Pancreas | Solid Tumour | Adenocarcinoma of the Colorectal
-
University of Michigan Rogel Cancer CenterCompletedAdenocarcinoma of the PancreasUnited States
-
National Cancer Institute, NaplesRecruitingAdenocarcinoma of the PancreasItaly, Spain
-
West Virginia UniversityRecruitingAdenocarcinoma of the PancreasUnited States
-
Baptist Health South FloridaAstraZenecaTerminatedAdenocarcinoma of the PancreasUnited States
-
Institut de Recherches Internationales ServierNot yet recruitingMetastatic Adenocarcinoma of the PancreasJapan
-
National Taiwan University HospitalRecruitingDuctal Adenocarcinoma of the PancreasTaiwan
-
Eastern Regional Medical CenterTerminatedMetastatic Adenocarcinoma of the PancreasUnited States
Clinical Trials on dasatinib
-
Bristol-Myers SquibbCompletedPharmacokinetic Study in Healthy ParticipantsUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completed
-
National Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell MyelomaUnited States
-
Hyoung Jin KangNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus CancerUnited States
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedCompleted
-
Peking University Cancer Hospital & InstituteUnknownGastrointestinal Stromal TumorChina
-
Kanto CML Study GroupUnknownMyelogenous Leukemia, Chronic, Chronic PhaseJapan
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbCompleted
-
Swiss Group for Clinical Cancer ResearchCompletedGastrointestinal Stromal TumorFrance, Switzerland, Germany, Finland